Smartkarma Originals
China Population Policies Impact on Healthcare Companies Series – Part 2
Several regions have successively introduced policies to encourage childbirth, so we analyzed the recent policy updates. Based on Livzon/BGI...
Smartkarma Originals
China Population Policies Impact on Healthcare Companies Series – Part 4
Different provinces expand coverage for assisted reproductive services in medical insurance. Livzon missed expectation in 2023.US sanction on BGI...
China Healthcare Weekly (Apr.6) - Boom of TCM Injections Is Coming, Defects in GLP-1s, Sino Biopharm
Payment policy relaxation will drive rapid sales growth of TCM injection.GLP-1 has defects-patients will lose not only fat but also muscle. Mr...
Pre-IPO TYK Medicines - Survival Risk Is Imminent, with Limited Highlights in the Pipeline
Except TY-9591 for brain metastases from NSCLC, the rest pipeline has little highlight but with fierce competition.As a biotech with no...
Smartkarma Originals